A baby has been treated with a customized CRISPR gene editing therapy, reportedly for the first time, for a rare metabolic disease. The treatment is described as a world first and has been trialled in a person, although some reports also mention its use in mice for a cardiac disease. The specifics of the treatment and the disease being targeted are not entirely clear, but it is characterized as a promising and landmark genetic treatment.